Abstract Number: 26 • 2014 ACR/ARHP Annual Meeting
Functional Osteoclasts Differentiate Spontaneously from the Rheumatoid Joint
Functional osteoclasts differentiate spontaneously from the rheumatoid joint Background/Purpose Osteoimmunology is a field of emerging interest in which bone formation and resorption are understood in…Abstract Number: 25 • 2014 ACR/ARHP Annual Meeting
DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair
Background/Purpose Patients with osteoporosis and the elderly have an increased risk of bone fracture. Currently, no biomarker is available to assess bone healing status in…Abstract Number: 24 • 2014 ACR/ARHP Annual Meeting
Netrin1 Is Highly Expressed and Required in Inflammatory Infiltrates in Wear Particle-Induced Osteolysis
Background/Purpose Osteoclasts play a critical role in homeostatic bone turnover and pathologic bone destruction. Netrin-1, expressed in the marrow only by osteoclast precursors, acts in…Abstract Number: 23 • 2014 ACR/ARHP Annual Meeting
Activation of EPAC1/2 Is Essential for Osteoclast Formation By Modulating NFkB Nuclear Translocation and Actin Cytoskeleton Rearrangements
Background/Purpose Bisphosphonates inhibit osteoclast differentiation/function via inhibition of Rap1A isoprenylation and cytoskeletal assembly. As Rap1 is the effector of EPAC proteins (exchange protein directly activated…Abstract Number: 1 • 2014 ACR/ARHP Annual Meeting
Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune clotting disorder of unknown etiology targeting a major autoantigen, β2-glycoprotein I (β2GPI). Infectious triggers have been implicated in…Abstract Number: L12 • 2014 ACR/ARHP Annual Meeting
Immunological Phenotyping of a Cohort of American Travelers with Chikungunya Viral Arthritis
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that spread to the United States in 2014. After an initial period of acute…Abstract Number: L8 • 2014 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Lupus Nephritis
Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE). We now have technologies that allow us to identify these factors…Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting
Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…Abstract Number: L20 • 2014 ACR/ARHP Annual Meeting
BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Background/Purpose: Over the first 16 wks of this phase 3 double-blind (DB) comparative effectiveness clinical trial, the comparable proportion of ACR20 responders for BOW015 (a…Abstract Number: 15 • 2014 ACR/ARHP Annual Meeting
Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Background/Purpose: Several immunoassays are available for the detection of anti-cardiolipin (aCL) and anti-beta2glycoprotein I antibodies (anti-B2GPI), but standardization and harmonization of these tests is an…Abstract Number: 14 • 2014 ACR/ARHP Annual Meeting
Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists
Background/Purpose: Management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state whilst balancing the bleeding risks of anticoagulant therapy. In a minority of APS…Abstract Number: 13 • 2014 ACR/ARHP Annual Meeting
Eculizumab in Antiphospholipid Antibody Syndrome
Background/Purpose Antiphospholipid syndrome (APS) is defined as the occurrence of venous or arterial thrombosis and/or pregnancy morbidity, in the presence of serological evidence of antiphospholipid…Abstract Number: 12 • 2014 ACR/ARHP Annual Meeting
Non-Criteria Antiphospholipid Antibodies in Obstetrical “seronegative Anti-Phospholipid syndrome”
Background/Purpose The aims of our prospective study were to determine the prevalence of non-criteria aPL and their clinical relevance in a seronegative population with pregnancy…Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…Abstract Number: 9 • 2014 ACR/ARHP Annual Meeting
A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation
Background/Purpose: Antiphospholipid antibody (aPL) positive patients undergoing kidney transplantation (Tx) are at increased risk for perioperative complications. The objective of this study was to analyze…